Full Text View
Tabular View
No Study Results Posted
Related Studies
Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer (MEDOBREC)
This study is currently recruiting participants.
Verified May 2012 by University of Bergen
Study NCT00496795   Information provided by University of Bergen

First Received on July 3, 2007.   Last Updated on May 16, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Primary Breast Cancer
Additional conditions recognized in this trial
Breast Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
docetaxel 2-weekly
pegfilgrastim 6mg injections
Additional drug interventions recognized in this trial
Docetaxel
Epirubicin
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
University of Bergen
Haukeland University Hospital


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services